



Trulance® (plecanatide) – New indication

- On January 25, 2018, [Synergy Pharmaceuticals announced](#) the FDA approval of [Trulance \(plecanatide\)](#) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
- Trulance is also approved for the treatment of adults with chronic idiopathic constipation.
- IBS is a chronic gastrointestinal disorder characterized by recurrent abdominal pain and associated with two or more of the following: related to defecation, associated with a change in the frequency of stool, or associated with a change in the form of the stool. IBS can be subtyped by the predominant stool form: IBS-C, diarrhea (IBS-D) or mixed (IBS-M). Those within the IBS-C subtype experience hard or lumpy stools > 25% of the time they defecate, and loose or watery stools < 25% of the time.
 - It is estimated that the prevalence of IBS-C in the U.S. adult population is approximately 4 – 5%.
- The new indication for Trulance was demonstrated in two placebo-controlled, 12-week studies of 1,453 patients with IBS-C. The efficacy of Trulance was assessed using a responder analysis based on abdominal pain intensity and a stool frequency responder endpoint.
 - In the first study, 30% of Trulance-treated patients and 18% of placebo-treated patients were considered responders (treatment difference: 12% [95% CI: 6, 19]).
 - In the second study, 21% of Trulance-treated patients and 14% of placebo-treated patients were considered responders (treatment difference: 7% [95% CI: 2, 13]).
- Trulance carries a boxed warning for risk of serious dehydration in pediatric patients.
- The recommended dosage of Trulance for both indications is 3 mg orally once daily.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.